NCT06925594招募中3 期
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Human TH-SC01 Cell Injection in the Treatment of Anal Fistulas in Patients With Non-active/Mildly Active Crohn's Disease
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.1 个研究点 分布在 1 个国家目标入组 228 人开始时间: 2025年3月20日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 228
- 试验地点
- 1
- 主要终点
- The proportion of subjects achieved combined remission
研究概览
简要总结
The purpose of this study is to evaluate the efficacy of human TH-SC01 cell injection for the treatment of perianal fistulas in Crohn's Disease over 24 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •Subjects with Crohn's disease diagnosed at least 6 months earlier according to the Chinese Consensus Opinion on the Diagnosis and Treatment of Inflammatory Bowel Diseases (Beijing, 2018)
- •Subjects with active perianal fistula and non active luminal CD defined by a CDAI ≤
- •Presence of perianal fistulas with a maximum of 2 fistulas (internal openings) and a maximum of 3 external openings, assessed by clinical assessment and MRI.
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to
- •American Society of Anesthesiologists (ASA) physical status classification of grade I to grade II.
- •All subjects and their partners were not planning to have a child from screening to the end of the trial and agreed to use effective non-drug contraception during the trial.
排除标准
- •Subjects allergic to human serum albumin, human platelet lysate, gentamicin sulfate, anesthetic drugs or MRI contrast agents.
- •Subjects with active infection evaluated by the investigator
- •Subjects with active Crohn's disease before drug administration or have not completed the induction-phase treatment.
- •Subjects with abscess or collections >2 cm.
- •Rectal and/or anal stenosis , if this means a limitation for any surgical procedure
- •Subjects with concurrent active proctitis.
- •Subjects with other fistulas such as rectum/anal canal-vaginal fistulas or rectum-bladder fistulas.
- •Patients have undergone a diverting stoma operation in the past, except for patients have completed stoma closure at least one month before drug administration.
- •Patients plan to undergo surgery in the perianal area during the trial period due to other diseases other than anal fistula.
- •Subjects with abnormal laboratory results: liver function: total bilirubin >=1.5 × ULN, and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >=2 × ULN; renal function: creatinine clearance below 60 mL/minute calculated using Cockcroft-Gault formula or by serum creatinine >=1.5 × upper limit of normal (ULN).
- •Serum virology test (HBeAg, HCV antibody, HIV antibody, Treponema pallidum antibody) positive.
- •Subjects with malignant tumors or a history of malignant tumors.
- •Subjects with congenital or acquired immunodeficiency.
- •Contraindication to MRI scan
- •Current or recent history of abnormal, severe, progressive, uncontrolled hepatic, haematological, gastrointestinal (except CD), endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral disease.
- •Subjects received stem cell treatment within two years prior to screening.
- •Patient with ongoing steroid treatment or treated with steroids in the last 4 weeks.
- •Patient undergone major surgical operations (such as orthopedic surgery, abdominal surgery) within one month before drug administration, or Patient plan to receive surgeries during the study period (except for the surgeries required by the procedures of this trial).
- •Patients with a history of drug abuse or alcoholism (Criteria for alcoholism: having a long-term drinking history of more than 5 years, with the amount of ethanol equivalent to ≥40g/d for men and ≥20g/d for women, or having a history of heavy drinking within 2 weeks, with the amount of ethanol equivalent to >80g/d. The conversion formula for the amount of ethanol (g) = the amount of alcohol consumed (ml) × the ethanol content (%) × 0.8).
- •Pregnant or lactating women.
- •Patients with a history of diverting ostomy, except those who have undergone stoma reversal at least 1 month prior to drug administration.
- •Other diseases or conditions that the investigator deems inappropriate for participating in this clinical trial, such as poor subject compliance and the expectation of being unable to complete follow-up and evaluation.
结局指标
主要结局
The proportion of subjects achieved combined remission
时间窗: 24 weeks
Combined Remission of perianal fistulising Crohn's disease defined as the all treated external openings achieved clinical remission at week 24， and absence of collections \> 2 cm of the treated perianal fistulas confirmed by centrally blinded MRI assessment by week 24.
次要结局
- The proportion of subjects achieved clinical remission(24 weeks ，52 weeks and104 weeks)
- The proportion of subjects achieved a clinical response(24 weeks，52 weeks and104 weeks)
- The proportion of subjects recurrence(24 weeks，52 weeks and104 weeks)
- Time to achieve clinical remission, clinical response and recurrence(24 weeks，52 weeks and104 weeks)
- The proportion of subjects achieved combined remission(52 weeks and104 weeks)
- VAS score(24 weeks，52 weeks and104 weeks)
- Perianal Disease Activity Index (PDAI)(24 weeks，52 weeks and104 weeks)
- Crohn's Disease Activity Index (CDAI) score(24 weeks，52 weeks and104 weeks)
- Inflammatory Bowel Disease Questionnaire（IBDQ）score(24 weeks，52 weeks and104 weeks)
- Anal sphincter function：Wexner incontinence score(24 weeks，52 weeks and104 weeks)
- peripheral blood cytokines(2 weeks，4 weeks ，8 weeks ，12weeks and 24 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
The Purpose of This Study is to Evaluate the Safety and Efficacy of Human TH-SC01 Cell Injection in the Treatment of Complex Perianal FistulaComplex Perianal FistulasNCT05677672Jiangsu Topcel-KH Pharmaceutical Co., Ltd.84
已完成
1 期
A Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's DiseasePerianal FistulaCrohn's DiseaseNCT05626023Jiangsu Topcel-KH Pharmaceutical Co., Ltd.9
已完成
1 期
Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242HealthyNCT03785054Heptares Therapeutics Limited71
进行中（未招募）
1 期
A Study of iPS Cell-derived Cardiomyocyte Spheroids (HS-001) in Patients With Heart Failure (LAPiS Study)Ischemic Heart DiseaseHeart FailureNCT04945018Heartseed Inc.10
Unknown
1 期
The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA COVID-19 Vaccine.COVID-19SARS-CoV-2 InfectionNCT05043311Sinocelltech Ltd.300